Overview of high-risk HPV's 16 and 18 infected cervical cancer: Pathogenesis to prevention

Biomedicine and Pharmacotherapy

Volumn 70, Issue C, 2015, Pages 103-110

  Ramakrishnan, Sabitha ^a   Partricia, Steena ^a   Mathan, Ganeshan ^a  

^a BHARATHIDASAN UNIVERSITY   (India)

Author keywords

Biomarkers; Cervical cancer; HPV 16; HPV 18; Oncoproteins; Treatments; Vaccinations

Indexed keywords

BACTERIAL VECTOR; CAPSID PROTEIN L1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DENDRITIC CELL VACCINE; DNA VACCINE; E5 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KALININ; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS VECTOR; WART VIRUS VACCINE; ANTIVIRUS AGENT;

DISEASE ASSOCIATION; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 16 INFECTION; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 18 INFECTION; INFECTION PREVENTION; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; UTERINE CERVIX CANCER; VACCINATION; FEMALE; PATHOGENICITY; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

ANTIVIRAL AGENTS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84927518228     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.041     Document Type: Review

References (106)

1. Bruni L., Barrionuevo-Rosas L., Serrano B., Brotons M., Albero G., Cosano R., et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and related diseases in India. Summary report 2014, 8-22.
2. Walboomers J.M.M., Meijer C.J.L.M. Do HPV-negative cervical carcinomas exist?. J Pathol 1997, 181:253-254.
3. Ermina Iljazovicemail, Marisa Mena, Sara Tous, Laia Alemany, Feda Omeragić, Azra Sadiković, et al. Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina. Cancer Epidemiol 2014, 38(5):504-510.
4. Munoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359(9312):1093-1101.
5. John D. Division of Virology 2006, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK.
6. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., et al. overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J Cancer 2001, 92:276-284.
7. International Agency for Research on Cancer (Monograph) 2007.
8. Thierry F., Benotmane M.A., Demeret C., Mori M., Teissier S., Desaintes O. A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer Res 2004, 64:895-903.
9. Brown D.R., Fan L., Jones J., Bryan J. Colocalization of human papillomavirus type 11 E1, E4 and L1 proteins in human foreskin implants grown in athymic mice. Virology 1994, 201:46-54.
10. Crusius K., Auvinen E., Alonso A. Enhancement of EGF and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997, 15:1437-1444.
11. Park T.W., Fujiwara H., Wright T.C. Molecular biology of cervical cancer and its precursors. Cancer 1995, 76:1902-1913.
12. http://www.cancerresearchuk.org/about-cancer/type/cervical-cancer/about/the-cervix.
13. http://immunopaedia.org.za/index.php?id=799.
14. DeMay M. Practical principles of cytopathology. Revised edition 2007, American Society for Clinical Pathology Press, Chicago, IL, [ISBN: 978-0- 89189-549-7].
15. http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-staged.
16. Hurlin I.P.J., Kaur P., Smith P.P., Perez-Reyes N., Blanton R.A., McDougall J.K. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames. J Gen Virol 1989, 70:1261-1266.
17. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989, 8:3905-3910.
18. Jabbar S., Strati K., Shin M.K., Pitot H.C., Lambert P.F. Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology 2010, 407(1):60-67.
19. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010, 10(8):550-560.
20. Straight S.W., Hinkle P.M., Jewers R.J., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993, 67:4521-4532.
21. Crusius K., Auvinen E., Alonso A. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res 1998, 241:76-83.
22. Steenburgen., Renske D.M. Jillian de Wilde, Saskia M. Wilting, Antoinette A.T.P. et al IARC monographs-90.
23. Kim M.H., Seo S.S., Song Y.S., Kang D.H., Park I.A., Kang S.B., et al. Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 2003, 90:83-90.
24. Ishikawa H1, Ohno T., Kato S., Wakatsuki M., Iwakawa M., Ohta T., et al. Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2006, 66:1347-1355.
25. Sokbom K., Moon H.K., In Ae Parkd, Jae Weon K., Noh H.P., Daehee K., et al. Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix. Cancer Lett 2006, 237:305-311.
26. Gaffney D.K., Holden J., Davis M., Zempolich K., Murphy K.J., Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001, 49:1213-1217.
27. Kim SH1, Juhnn Y.S., Kang S., Park S.W., Sung M.W., Bang Y.J., et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1, 2 and PI3K/Akt. Cell Mol Life Sci 2006, 63:930-938.
28. Zhang B1, Spandau D.F., Roman A. E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J Virol 2002, 76:220-231.
29. Lefort K., Mandinova A., Ostano P., Kolev V., Calpini V., Kolfschoten I., et al. Notch1 is a p53 target gene involve in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK {alpha} kinases. Genes Dev 2007, 21:562-577.
30. Yugawa T., Handa K., Narisawa-Saito M., Ohno S.I., Fujita M., Kiyono T. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol Cell Biol 2007, 27:3732-3742.
31. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661.
32. Rangarajan A., Talora C., Okuyama R., Nicolas M., Mammucari C., Oh H., et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001, 20:3427-3436.
33. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003, 33:416-421.
34. Talora C., Sgroi Dennis C., Christopher P., Crum G., Dotto P. Specific down-modulation of Notch1 signaling in cervical cancer cells is transformation required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002, 16:2252-2263.
35. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
36. Storey A., Thomas M., Kalita A., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393:229-234.
37. Thomas M., Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 1999, 80:1513-1517.
38. Garnett T.O., Filippova M., Duerksen-Hughes P.J. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16, E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006, 13:1915-1926.
39. Pendino F., Tarkanyi I., Dudognon C., Hillion J., Lanotte M., Aradi J., et al. Telomeres and telomerase: pharmacological targets for new anticancer strategies?. Curr Cancer Drug Targets 2006, 6:147-180.
40. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380:79-82.
41. Veldman T., Liu X., Yuan H., Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci 2003, 100:8211-8216.
42. Endl E., Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000, 257(2):231-237.
43. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182(3):311-322. 2000.
44. Koh J., Enders G.H., Dynlacht B.D., Harlow E. Tumour derive p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995, 375:506-510.
45. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
46. Khleif S.N., Degregori J., Yee C.L., Otterson G.A., Kaye F.J., Nevins J.R., et al. M"Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 1996, 93(9):4350-4354.
47. Sano T., Oyama T., Kashiwabara K., Fukuda T., Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998, 153(6):1741-1748.
48. Santin A.D., Zhan F., Bignotti E., Siegel E.R., Cane S., Bellone S., et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005, 331:269-291.
49. Murphy N., Ring M., Heffron C.C., King B., Killalea A.G., Hughes C., et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005, 58(5):525-534.
50. Malinowski D.P. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. BioTechniques 2005, 17-23.
51. Freeman A., Morris L.S., Mills A.D., Stoeber K., Laskey R.A., Williams G.H., et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999, 5(8):2121-2132.
52. Gonzalez M.A., Tachibana K.E.K., Laskey R.A., Coleman N. Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 2005, 5(2):135-141.
53. Williams G.H., Stoeber K. Cell cycle markers in clinical oncology. Curr Opin Cell Biol 2007, 19(6):672-679. Oncology.
54. Sherman L., Alloul N., Golan I., Durst M., Baram A. Expression and splicing patterns of human papillomavirus type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV 16, and in cell lines established from cervical cancers. Int J Cancer 1992, 50(3):356-364.
55. McMurray H.R., McCance D.J. Human papillomavirus type 16, E6 activates TERT gene transcription through induction of c-Myc and release of USF mediated repression. J Virol 2003, 77:9852-9861.
56. Pyke C., Romer J., Kallunki P., Lund L.R., Ralfkiaer E., Dano K., et al. The gamma 2 chain of kalinin/laminin-5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994, 145:782-791.
57. Soini Y., Maatta M., Salo S., Tryggvason K., Autio-Harmainen H. Expression of the laminin gamma 2 chain in pancreatic adenocarcinoma. J Pathol 1996, 180:290-294.
58. Sordat I., Bosman F.T., Dorta G., Rousselle P., Aberdam D., Blum A.L., et al. Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J Pathol 1998, 185:44-52.
59. Giannelli G., Antonaci S. Biological and clinical relevance of laminin-5 in cancer. Clin Exp Metastasis 2000, 18:439-443.
60. Haas K.M., Berndt A., Stiller K.J., Hyckel P., Kosmehl H. A comparative quantitative analysis of laminin-5 in the basement membrane of normal, hyperplastic, and malignant oral mucosa by confocal immunofluorescence imaging. J Histochem Cytochem 2001, 49:1261-1268.
61. Goel M.M., Mehrotra A., Singh U., Gupta H.P., Misra J.C. MIB-1 and PCNA immunostaining as a diagnostic adjunct to cervical pap smear. Diagn Cytopathol 2005, 33:15-19.
62. Von Hoven K.H., Kovatich A.J., Oliver R.E., Nobel M., Dunton C.J. Immunocytochemical detection of squamous intraepithelial lesion in cervical smears. Mod Pathol 1996, 9:407-411.
63. Mathur S.P., Mathur R.S., Young R.C. Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol 2000, 44:222-230.
64. Janmaat M.L., Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2003, 8:576-586.
65. Nasu S., Ang K.K., Fan Z., Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001, 51:474-477.
66. Pillai M.R., Jayaprakash P.G., Nair M.K. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 1998, 124:456-461.
67. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
68. Yoshinouchi M., Yamada T., Kizaki M., Fen J., Koseki T., Ikeda Y., et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003, 8:762-768.
69. Teni B., Maria V. Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 2003, 10(6):1663-1682.
70. Tsai T.H. Analytical approaches for traditional chinese medicines exhibiting antineoplastic activity. J Chromatogr B Biomed Sci Appl 2001, 764:27-48.
71. Barnard D.L., Huffman J.H., Morris J.L., Wood S.G., Hughes B.G., Sidwell R.W. Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. Antivir Res 1992, 17:63-77.
72. Lee H.Z. Effects and mechanisms of emodin on cell death in human lung squamous cell carcinoma. Br J Pharmacol 2001, 134:11-20.
73. Malterud K.E., Farbrot T.L., Huse A.E., Sund R.B. Antioxidant and radical scavenging effects of anthraquinones and anthrones. Pharmacology 1993, 47(Suppl.1):77-85.
74. Muller S.O., Eckert I., Lutz W.K., Stopper H. Genotoxicity of the laxative drug components emodin, aloe-emodin and danthron in mammalian cells: topoisomerase II mediated?. Mutat Res 1996, 371:165-173.
75. Wang H.H., Chung J.G., Ho C.C., Wu L.T., Chang S.H. Aloeemodin effects on arylamine N-acetyltransferase activity in the bacterium Helicobacter pylori. Planta Med 1998, 64:176-178.
76. Kaarthigeyan K. Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol 2012, 33(1):7-12.
77. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185:251-257.
78. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Stephanie L., Schiller J.T., Bobst M., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003, 95:1128-1137.
79. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1651.
80. Serrano B., Alemany L., Alonso de Ruiz P., Tous S., Aurelho Lima M., Bruni L., et al. Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). CANEP 2014, [Accepted].
81. Padilla-Paz L.A. Human papillomavirus vaccine: history, immunology, current status, and future prospects. Clin Obstet Gynecol 2005, 48:226-240.
82. Ahn W.S., Bae S.M., Kim T.Y., Kim T.G., Lee J.M., Namkoong S.E., et al. Therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7- associated cervical cancer animal model. Hum Gene Ther 2003, 14:1389-1399.
83. Jochmus-Kudielka I., Schneider A., Braun R., Kimmig R., Koldovsky U., Schneweis K.E. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989, 81:1698-1704.
84. Borysiewicz L.K., Fiander A., Nimako M., Man S. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523-1527.
85. Jabbar I.A., Fernando G.J., Saunders N., Aldovini A., Young R., Malcolm K., et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000, 18:2444-2453.
86. Lacey C.J., Thompson H.S., Monteiro E.F., O'Neill T., Davies M.L., Holding F.P. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999, 179:612-618.
87. Roden R.B., Ling M., Wu T.C. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004, 35:971-982.
88. Kim T.W., Hung C.F., Boyd D.A., He L., Lin C.T., Kaiserman D., et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003, 112:109-117.
89. Santin A.D., Hermonat P.L., avaggi Chiriva-Internati, Zhan D.J., et al. Induction of human papillomavirus- specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999, 73:5402-5410.
90. Mahdavi A., Bardley J. Vaccines against Human Papillomavirus and cervical cancer: promises and challenges. Oncologist 2005, 10:528-538.
91. Centers for Disease Control Prevention (CDC) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(20):626-629.
92. Richwine Lisa. Update 2-U.S. health officials back safety of Merck vaccine 2009, 11-12. Reuters.
93. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111:278-285.
94. Bahnassy A.A., Zekri A.R., Saleh M., Lotayef M., Moneir M., Lotayef M., et al. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol 2007, 7:4.
95. Nieh S., Chen S.F., Chu T.Y., Lai H.C., Fu E. Expression of p16INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol 2003, 91(1):201-208.
96. Nieh S., Chen S.F., Chu T.Y., Lai H.C., Lin Y.S., Fu E., et al. Is p16INK4A expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol 2005, 97(1):35-40.
97. Tsoumpou I., Arbyn M., Kyrgiou M., Wentzensen N., Koliopoulos G., Martin-Hirsch P., et al. EP16INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009, 35(3):210-220.
98. Yoshida T., Fukuda T., Sano T., Kanuma T., Owada N., Nakajima T. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer 2004, 102(2):100-108.
99. Hilfrich R., Hariri J. Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quantitative Cytol Histol 2008, 30(2):78-82.
100. Rauber D., Mehlhorn G., Fasching P.A., Beckmann M.W., Ackermann S. Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions. Eur J Obstet Gynecol Reprod Biol 2008, 140(2):258-262.
101. Birner P., Bachtiary B., Dreier B., Schindl M., Joura E.A., Breitenecker G., et al. Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions. Modern Pathol 2001, 14(7):702-709.
102. Griesser H., Sander H., Hilfrich R., Moser B., Schenck U. HPV vaccine protein L1 predicts disease outcome of HPV high risk positive early squamous dysplastic lesions. Am J Clin Pathol 2009, 132(6):840-845.
103. Sonnenberg A., de Melker A.A., Martinez de Velasco A.M., Janssen H., Calafat J., Niessen C.M. Formation of hemidesmosomes in cells of a transformed murine mammary tumor cell line and mechanisms involved in adherence of these cells to laminin and kalinin. J Cell Sci 1993, 106:1083-1102.
104. Goldfinger L.E., Hopkinson S.B., deHart G.W., Collawn S., Couchman J.R., Jones J.C. The alpha3 laminin subunit, alpha6beta4 and alpha3beta1 integrin coordinately regulate wound healing in cultured epithelial cells and in the skin. J Cell Sci 1999, 112:2615-2629.
105. Zhang K., Kramer R.H. Laminin-5 deposition promotes keratinocyte motility. Exp Cell Res 1996, 227:309-322.
106. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluation in human malignancies. Semin Cancer Biol 1990, 1:199-206.